Hotchkis & Wiley Capital Management LLC Sells 24,786 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Key Points

• Hotchkis & Wiley Capital Management LLC reduced its holdings in Zimmer Biomet by 1.5%, owning 1,645,955 shares valued at approximately $186 million after selling 24,786 shares in the first quarter.
• Analysts have mixed ratings on Zimmer Biomet, with a consensus rating of Hold and an average target price of $111.44, while recent price targets range from $91.00 to $128.00.
• Zimmer Biomet reported a quarterly earnings beat with $2.07 EPS on revenue of $2.08 billion, a 7% increase year-over-year, and set FY 2025 EPS guidance at $8.100-$8.300.

Hotchkis & Wiley Capital Management LLC trimmed its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 1.5% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,645,955 shares of the medical equipment provider's stock after selling 24,786 shares during the quarter. Hotchkis & Wiley Capital Management LLC owned 0.83% of Zimmer Biomet worth $186,289,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also made changes to their positions in ZBH. Garde Capital Inc. purchased a new stake in shares of Zimmer Biomet in the first quarter worth approximately $29,000. Menard Financial Group LLC acquired a new position in Zimmer Biomet in the fourth quarter worth approximately $30,000. Washington Trust Advisors Inc. acquired a new position in Zimmer Biomet in the first quarter worth approximately $30,000. Columbia River Financial Group LLC acquired a new position in Zimmer Biomet in the first quarter worth approximately $30,000. Finally, Accent Capital Management LLC acquired a new position in Zimmer Biomet in the first quarter worth approximately $35,000. 88.89% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Zimmer Biomet

In other news, insider Sang Yi sold 1,000 shares of the stock in a transaction that occurred on Wednesday, June 11th. The stock was sold at an average price of $95.00, for a total value of $95,000.00. Following the completion of the sale, the insider directly owned 20,424 shares of the company's stock, valued at approximately $1,940,280. This represents a 4.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.70% of the company's stock.

Zimmer Biomet Stock Performance

ZBH stock traded down $0.67 during midday trading on Wednesday, hitting $106.87. 846,053 shares of the company traded hands, compared to its average volume of 2,043,039. Zimmer Biomet Holdings, Inc. has a twelve month low of $89.22 and a twelve month high of $116.71. The company has a quick ratio of 0.96, a current ratio of 1.87 and a debt-to-equity ratio of 0.54. The business has a 50 day simple moving average of $96.17 and a 200-day simple moving average of $99.34. The stock has a market capitalization of $21.17 billion, a price-to-earnings ratio of 26.00, a price-to-earnings-growth ratio of 2.11 and a beta of 0.68.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share for the quarter, beating the consensus estimate of $1.98 by $0.09. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The company had revenue of $2.08 billion during the quarter, compared to analysts' expectations of $2.06 billion. During the same period in the prior year, the business earned $2.01 earnings per share. Zimmer Biomet's revenue for the quarter was up 7.0% compared to the same quarter last year. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, equities research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be given a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 0.9%. Zimmer Biomet's dividend payout ratio is 23.36%.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on ZBH shares. Stifel Nicolaus set a $115.00 price objective on Zimmer Biomet and gave the stock a "buy" rating in a report on Tuesday, May 6th. Wells Fargo & Company dropped their price objective on Zimmer Biomet from $113.00 to $98.00 and set an "equal weight" rating on the stock in a report on Tuesday, May 6th. Royal Bank Of Canada increased their price target on Zimmer Biomet from $112.00 to $115.00 and gave the company an "outperform" rating in a report on Friday, August 8th. UBS Group increased their price target on Zimmer Biomet from $91.00 to $96.00 and gave the company a "sell" rating in a report on Friday, August 8th. Finally, The Goldman Sachs Group lowered their price target on Zimmer Biomet from $120.00 to $104.00 and set a "neutral" rating on the stock in a report on Tuesday, May 6th. Nine investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of "Hold" and an average price target of $111.44.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.